MedPath

S-ICD® System IDE Clinical Study

Not Applicable
Completed
Conditions
Tachycardia, Ventricular
Registration Number
NCT01064076
Lead Sponsor
Boston Scientific Corporation
Brief Summary

This clinical study is designed to evaluate the safety and effectiveness of the subcutaneous implantable defibrillator (S-ICD) System.

Detailed Description

This clinical study is a prospective, non-randomized, multicenter clinical study without a control group conducted in the United States, Europe, and New Zealand.

Patients meeting eligibility criteria for implanting an S-ICD System will be enrolled in this clinical study, implanted with an S-ICD System, and followed prior to hospital discharge, and post-implant at 30 days, 90 days, and 180 days. After the 180-day post-implant follow-up visit, patients will continue to be followed semi-annually until study closure.

Eligible patients enrolled in this clinical study may also participate in the chronic conversion sub-study.

The safety endpoint will be evaluated through the use of a 180-day S-ICD System complication-free rate. The effectiveness endpoint will be evaluated using an induced ventricular fibrillation (VF) conversion efficacy rate. Spontaneous episodes and chronic conversion testing data will be evaluated using descriptive statistics to provide additional data supporting the continued chronic performance of the S-ICD System.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
330
Inclusion Criteria
  • For patients without an existing transvenous device

    • Patient meets Class I, Class IIa or Class IIb indications/recommendations for ICD implantation per the current published guidelines at the time of enrollment

  • For patients with an existing transvenous device

    • Patient requires replacement or revision of an existing implanted transvenous ICD system

  • Age is ≥ 18 years

  • An appropriate pre-operative ECG per template provided

Exclusion Criteria
  • Any condition which precludes the subject's ability to comply with the study requirements, including completion of the study.
  • Females who are pregnant or lactating and pre-menopausal women who are unwilling to use adequate birth control for the duration of the study.
  • Participation in any other investigational study without prior written consent from the study sponsor.
  • Patients with a serious medical condition and life expectancy of less than one year.
  • Patients with documented spontaneous and frequently recurring VT that is reliably terminated with anti-tachycardia pacing, unless the patient is not a candidate for a transvenous ICD system.
  • Patients with existing epicardial patches or subcutaneous electrodes in the left thoracic quadrant.
  • Patients with unipolar pacemakers or implanted devices that revert to unipolar pacing.
  • Patients with severely impaired kidney function as measured by a Cockcroft-Gault Glomerular Filtration Rate (GFR) with an estimated GFR ≤ 29.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Percentage of Participants Free of Type I Complications at 180 Days.180 days

Percentage of Participants Free of Type I Complications at 180 days compared to the performance goal of 79%. Type I complications are those caused by the S-ICD System.

Percentage of Participants Who Pass Induced VF Conversion TestImplant/Pre-Discharge

Percentage of participants who pass induced VF conversion test was compared to a performance goal of 88%. Definition of a success was two consecutive successful 65 joule shocks out of four attempts in the same polarity.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (33)

Arizona Arrhythmia Consultants

🇺🇸

Scottsdale, Arizona, United States

University of Southern California

🇺🇸

Los Angeles, California, United States

Foothill Cardiology

🇺🇸

Pasadena, California, United States

CMCA / Sequoia Hospital

🇺🇸

Redwood City, California, United States

Sharp Grossmont Hospital

🇺🇸

San Diego, California, United States

Sharp Memorial Hospital

🇺🇸

San Diego, California, United States

Pacific Heart Institute

🇺🇸

Santa Monica, California, United States

South Bay Electrophysiology

🇺🇸

Torrance, California, United States

Washington Hospital Center

🇺🇸

Washington, District of Columbia, United States

Emory University School of Medicine

🇺🇸

Atlanta, Georgia, United States

Scroll for more (23 remaining)
Arizona Arrhythmia Consultants
🇺🇸Scottsdale, Arizona, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.